BGBIO.OL - BerGenBio ASA
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.4500 |
| Open | 0.4500 |
| Bid | 0.3665 x 0 |
| Ask | 0.3870 x 0 |
| Day's Range | 0.3505 - 0.4500 |
| 52 Week Range | 0.2520 - 16.0100 |
| Volume | |
| Avg. Volume | 1,239,420 |
| Market Cap | 37.585M |
| Beta (5Y Monthly) | 1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.1400 |
| Earnings Date | Aug 23, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.22 |
Fair Value
Related Research
PR NewswireBerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue
Reference is made to the stock exchange announcement by BerGenBio ASA (the "Company") on 22 May 2023 regarding approval by the Company's annual general meeting of a partially underwritten rights issue in the Company to raise gross proceeds of up to NOK 250 million (the "Rights Issue"), and the issuance of warrants to subscribers in the Rights Issue (the "Warrants").
PR NewswireBerGenBio ASA: Proposed partially underwritten rights issue
The board of directors of BerGenBio ASA (the "Company") has today, subject to approval by the Annual General Meeting (the "AGM") on 22 May 2023, resolved to carry out a rights issue of shares (the "New Shares") with preferential subscription rights for existing shareholders (the "Rights Issue") to raise gross proceeds of up to NOK 250 million. Subscribers in the Rights Issue will for every two New Shares allocated and subscribed receive one warrant to subscribe for one new share in the Company (
PR NewswireBerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced the first patient was dosed in a Phase 1b/2a trial evaluating bemcentinib in combination with the current standard of care, immune checkpoint inhibitor pembrolizumab and doublet chemotherapy, for the treatment of 1st line (1L) Non-Small Cell Lung Cancer (NSCLC) patients harboring STK11 mutations (STK11m).
PR NewswireBerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the fourth quarter ended December 31, 2022, and provided a business update.
PR NewswireBerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced topline data from BGBC008, a phase 2 trial evaluating its lead compound bemcentinib in combination with MSD's anti-PD-1 therapy pembrolizumab in 2L+ Non-Small Cell Lung Cancer (NSCLC) patients.
PR NewswireBerGenBio Announces the Establishment of Oncology Scientific Advisory Board
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced the formation of a scientific advisory board consisting of four world-renowned non-small cell lung cancer (NSCLC) experts from top oncology centers around the globe to enhance the development of bemcentinib for the treatment of NSCLC patients with STK11 mutations (STK11m).
PR NewswireBerGenBio reports third quarter 2022 financial results and provides business update
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.
PR NewswireBerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, and Meteva AS, a 27.23% shareholder in BerGenBio, today announced that they have entered into a shareholder loan facility, pursuant to which Meteva will make available to BerGenBio up to NOK 100 million.
PR NewswireBerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced the initiation of a Phase 1b/2a trial evaluating bemcentinib in combination with the current standard of care, checkpoint inhibitor pembrolizumab and doublet chemotherapy, for the treatment of 1st line (1L) Non-Small Cell Lung Cancer (NSCLC) patients harboring STK11 mutations (STK11m).
PR NewswireBERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, and Oslo University Hospital announced today that the first patient has been included in a study of BerGenBio's oral, highly selective AXL inhibitor, bemcentinib, as part of the EU-SolidAct trial in hospitalized COVID-19 patients.
- PR Newswire
BerGenBio reports second quarter and half year 2022 financial results and provides business update
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the second quarter and half year ended June 30, 2022 and provided a business update.